PriceTargets.com logo

Bruker - BRKR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $84.86
  • Forecasted Upside: 5.29%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$80.59 As of 04/25/2024 01:00 AM ET
▼ -1.61 (-1.96%)

This chart shows the closing price for BRKR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bruker Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRKR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRKR

Analyst Price Target is $84.86
▲ +5.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $84.86, with a high forecast of $102.00 and a low forecast of $72.00. The average price target represents a 5.29% upside from the last price of $80.59.

This chart shows the closing price for BRKR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Bruker. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$66.00 ➝ $74.00Low
3/1/2024UBS GroupBoost TargetBuy ➝ Buy$94.00 ➝ $102.00Low
2/15/2024UBS GroupBoost TargetBuy ➝ Buy$86.00 ➝ $94.00Low
2/14/2024CitigroupBoost TargetBuy ➝ Buy$80.00 ➝ $95.00Low
2/14/2024Stifel NicolausBoost TargetHold ➝ Hold$63.00 ➝ $81.00Low
2/14/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00 ➝ $90.00Low
12/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$72.00Low
12/13/2023Wolfe ResearchInitiated CoverageOutperform$80.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$70.00 ➝ $65.00Low
5/5/2023UBS GroupBoost Target$92.00 ➝ $98.00Low
5/5/2023CitigroupBoost Target$90.00 ➝ $95.00Low
4/19/2023The Goldman Sachs GroupBoost TargetSell$63.00 ➝ $70.00Low
2/10/2023CitigroupBoost TargetBuy$80.00 ➝ $90.00Low
11/16/2022CowenLower Target$75.00N/A
10/21/2022UBS GroupInitiated CoverageBuy$70.00Low
8/22/2022CitigroupUpgradeNeutral ➝ Buy$70.00 ➝ $80.00Low
4/13/2022The Goldman Sachs GroupLower TargetSell$73.00 ➝ $60.00Medium
2/14/2022SVB LeerinkBoost TargetOutperform$84.00 ➝ $85.00Medium
11/2/2021Wells Fargo & CompanyBoost TargetEqual Weight$85.00 ➝ $90.00High
9/9/2021SVB LeerinkBoost TargetOutperform$90.00 ➝ $100.00Low
8/3/2021Wells Fargo & CompanyBoost TargetEqual Weight$70.00 ➝ $85.00High
8/3/2021CitigroupBoost TargetNeutral$75.00 ➝ $85.00High
6/18/2021SVB LeerinkBoost TargetOutperform$80.00 ➝ $85.00Medium
5/6/2021BTIG ResearchBoost TargetBuy$73.00 ➝ $80.00Low
5/6/2021SVB LeerinkBoost TargetOutperform$70.00 ➝ $80.00Medium
2/17/2021CitigroupBoost Target$57.00 ➝ $65.00Low
2/17/2021Stifel NicolausBoost TargetIn-Line ➝ Hold$48.00 ➝ $65.00Low
2/5/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$50.00 ➝ $55.00Medium
1/27/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $70.00High
12/17/2020BTIG ResearchBoost TargetBuy$50.00 ➝ $64.00Medium
12/16/2020Smith Barney CitigroupBoost Target$47.00 ➝ $57.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageSell$50.00Low
11/16/2020Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
8/4/2020CitigroupBoost TargetNeutral$38.00 ➝ $47.00Medium
8/4/2020Wells Fargo & CompanyBoost TargetOverweight$42.00 ➝ $52.00High
8/4/2020SVB LeerinkBoost TargetOutperform$45.00 ➝ $50.00High
7/20/2020Bank of AmericaBoost TargetBuy$43.00 ➝ $49.00Medium
5/13/2020Needham & Company LLCReiterated RatingHoldLow
5/7/2020CitigroupLower TargetNeutral$40.00 ➝ $38.00High
5/7/2020Wells Fargo & CompanyLower TargetOverweight$50.00 ➝ $42.00High
5/7/2020Needham & Company LLCReiterated RatingHoldHigh
4/28/2020UBS GroupLower TargetNeutral$53.00 ➝ $41.00Low
4/2/2020Stifel NicolausLower TargetHold$52.00 ➝ $35.00High
4/2/2020Wolfe ResearchDowngradeMarket Perform ➝ Underperform$27.00High
3/31/2020Needham & Company LLCDowngradeStrong-Buy ➝ HoldHigh
3/30/2020Wells Fargo & CompanyLower Target$60.00 ➝ $50.00Medium
3/30/2020SVB LeerinkLower TargetOutperform$58.00 ➝ $46.00High
3/26/2020BarclaysUpgradeEqual Weight ➝ Overweight$52.00 ➝ $48.00High
3/20/2020CitigroupLower TargetNeutral$52.00 ➝ $40.00High
2/19/2020Needham & Company LLCBoost TargetStrong-Buy$62.00 ➝ $63.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$60.00Medium
1/6/2020CitigroupInitiated CoverageBuy$52.00Low
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$39.00High
12/23/2019Needham & Company LLCReiterated RatingBuy$62.00Low
11/14/2019Stifel NicolausInitiated CoverageHold$53.00High
9/27/2019Needham & Company LLCSet TargetBuy$58.00Low
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$52.00Low
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$32.00 ➝ $48.00Low
6/24/2019Needham & Company LLCSet TargetStrong-Buy$46.00 ➝ $57.00Low
6/24/2019BarclaysReiterated RatingHold$44.00Low
6/21/2019Bank of AmericaReiterated RatingNeutral ➝ Neutral$44.00 ➝ $52.00Low
6/21/2019Jefferies Financial GroupBoost TargetBuy$45.00 ➝ $56.00Low
6/21/2019BTIG ResearchBoost TargetBuy$57.00Low
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/6/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$39.00 ➝ $46.00Low
5/3/2019UBS GroupUpgradeSell ➝ Neutral$43.00High
5/3/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$40.00 ➝ $53.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 19 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 30 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 24 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 14 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 14 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Bruker logo
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $80.59
Low: $79.99
High: $81.50

50 Day Range

MA: $88.09
Low: $77.76
High: $94.27

52 Week Range

Now: $80.59
Low: $53.79
High: $94.86

Volume

1,091,983 shs

Average Volume

807,534 shs

Market Capitalization

$11.71 billion

P/E Ratio

27.60

Dividend Yield

0.24%

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Bruker?

The following Wall Street research analysts have issued reports on Bruker in the last twelve months: Citigroup Inc., JPMorgan Chase & Co., Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for BRKR.

What is the current price target for Bruker?

7 Wall Street analysts have set twelve-month price targets for Bruker in the last year. Their average twelve-month price target is $84.86, suggesting a possible upside of 5.9%. UBS Group AG has the highest price target set, predicting BRKR will reach $102.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $72.00 for Bruker in the next year.
View the latest price targets for BRKR.

What is the current consensus analyst rating for Bruker?

Bruker currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BRKR, but not buy more shares or sell existing shares.
View the latest ratings for BRKR.

What other companies compete with Bruker?

Other companies that are similar to Bruker include Bio-Rad Laboratories, Revvity, Avantor, Waters and 10x Genomics. Learn More about companies similar to Bruker.

How do I contact Bruker's investor relations team?

Bruker's physical mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company's listed phone number is (978) 663-3660 and its investor relations email address is [email protected]. The official website for Bruker is www.bruker.com. Learn More about contacing Bruker investor relations.